| Character | Value | Percent |
| Age |
|
|
| Median | 65 |
|
| Range | 57 - 86 |
|
| Performance status |
|
|
| 0 | 43 | 58.9 |
| 1 | 30 | 41.1 |
| Gleason score |
|
|
| ≤6 | 7 | 9.6 |
| 7 | 23 | 31.5 |
| ≥8 | 43 | 58.9 |
| Biopsy core % |
|
|
| ˂50% | 15 | 20.6 |
| ≥50% | 58 | 79.4 |
| PSA (ng/ml) |
|
|
| Median | 28 |
|
| Rang | 13 - 300 |
|
| Clinical Stage |
|
|
| T1 | 14 | 19.2 |
| T2 | 7 | 9.6 |
| T3 | 44 | 60.3 |
| T4 | 8 | 11 |
| Diabetes | 29 | 39.7 |
| Anticoagulant therapy | 14 | 19.2 |
| Androgen deprivation therapy (ADT) |
|
|
| ≤24 months | 59 | 80.8 |
| >24 months | 14 | 19.2 |